Characterization of NACK, an essential coactivator of Notch, in tumorigenesis
NACK(Notch 的重要共激活因子)在肿瘤发生中的表征
基本信息
- 批准号:9125782
- 负责人:
- 金额:$ 31.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-09-01 至 2018-07-31
- 项目状态:已结题
- 来源:
- 关键词:AffectBindingBreastCell SurvivalCellsClinical TrialsComplexDevelopmentDrug TargetingEmbryoEventFigs - dietaryGene FamilyGoalsHumanIndiumKnock-outKnockout MiceKnowledgeMaintenanceMalignant NeoplasmsMediatingModelingMolecularMonoubiquitinationMusNormal tissue morphologyOrganOrganogenesisPancreasPathway interactionsPhenotypePhosphorylationPhosphotransferasesPropertyProteinsRoleSolid NeoplasmSpecificitySystemTestingTherapeuticTissuesToxic effectTranscription CoactivatorTranscriptional ActivationTumor Markersbasecancer cellcancer therapycell transformationdesignefficacy testinggamma secretasein vivoinhibitor/antagonistlymphoid neoplasmmembermetaplastic cell transformationnotch proteinnovelnovel markerparalogous genetumortumor initiationtumorigenesis
项目摘要
DESCRIPTION (provided by applicant): Substantial evidence has demonstrated a role for the Notch gene family in multiple human cancers, including neoplasms of the lymphoid system, pancreas, breast and CNS. This transforming activity is an intrinsic property of Notch, which mediates its effects through a transcriptional regulatory complex. However, there remains a significant lack of knowledge with respect to the molecular events leading to the formation of the Notch transcriptional activation complex. Gamma secretase inhibitors (GSIs) are the only drugs targeting Notch that are being tested for efficacy in clinical trials. However, aberrantly expresse Notch intracellular domain (NICD) does not respond to GSI treatment, turning into a high priority the search of new elements in the notch pathway suitable to be pharmacologically targeted. With this purpose, we have searched for new components in the Notch transcriptional activation complex and have identified a novel Notch-associated protein, we termed Notch Activation Complex Kinase (NACK). NACK functions as a co-activator of Notch transcriptional activity and it is expressed in human tumors but not in the adjacent normal tissue. Furthermore, NACK is required for Notch-driven cell transformation. Our preliminary results convincingly identify NACK as a new member of the Notch transcriptional complex and a putative target to inhibit Notch pathway. The underlying hypothesis of this proposal is that NAK is a transcriptional co-activator implicated in tumorigenesis. Our goal is to characterize th molecular mechanisms regulating NACK function, to determine its role in tumorigenesis and to investigate the prospect of using NACK as a tumor biomarker and a putative pharmacological target in anti-cancer therapies. The specific aims of this proposal are: i) Characterize the molecular basis of the interaction between NACK and the Notch transcriptional regulatory complex~ ii) Characterize NACK function in vivo using a conditional NACK-KO mouse~ and iii) Determine the role of NACK in Notch-driven tumorigenesis. The long-range goal for these studies is to obtain a comprehensive understanding of NACK function in order to contribute to the rational design of cancer therapeutics
描述(由申请方提供):大量证据表明Notch基因家族在多种人类癌症中发挥作用,包括淋巴系统、胰腺、乳腺和CNS肿瘤。 这种转化活性是Notch的固有特性,其通过转录调节复合物介导其作用。然而,对于导致Notch转录激活复合物形成的分子事件,仍然存在显著的知识缺乏。 γ分泌酶抑制剂(GSI)是唯一正在临床试验中测试疗效的靶向Notch的药物。然而,异常表达的Notch胞内结构域(NICD)对GSI治疗没有反应,因此在Notch通路中寻找适合于靶向GSI的新元件成为高度优先事项。为此,我们已经在Notch转录激活复合物中寻找新的组分,并鉴定了一种新的Notch相关蛋白,我们称之为Notch激活复合物激酶(NACK)。 NACK作为Notch转录活性的共激活因子起作用,并且其在人肿瘤中表达,但不在邻近的正常组织中表达。此外,Notch驱动的细胞转化需要NACK。我们的初步结果令人信服地确定NACK作为一个新的成员的Notch转录复合物和一个假定的目标,以抑制Notch途径。 该提议的基本假设是,NAK是与肿瘤发生有关的转录共激活因子。本研究的目的是探讨NACK的分子调控机制,确定其在肿瘤发生中的作用,并探讨NACK作为肿瘤生物标志物和抗癌药物靶点的前景。该提议的具体目的是:i)表征NACK和Notch转录调控复合物之间相互作用的分子基础,ii)使用条件性NACK-KO小鼠表征NACK的体内功能,以及iii)确定NACK在Notch驱动的肿瘤发生中的作用。 这些研究的长期目标是获得对NACK功能的全面了解,以便有助于癌症治疗的合理设计
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANTHONY John CAPOBIANCO其他文献
ANTHONY John CAPOBIANCO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANTHONY John CAPOBIANCO', 18)}}的其他基金
Characterization of NACK, an essential coactivator of Notch, in tumorigenesis
NACK(Notch 的重要共激活因子)在肿瘤发生中的表征
- 批准号:
8526437 - 财政年份:2012
- 资助金额:
$ 31.75万 - 项目类别:
Characterization of NACK, an essential coactivator of Notch, in tumorigenesis
NACK(Notch 的重要共激活因子)在肿瘤发生中的表征
- 批准号:
8701256 - 财政年份:2012
- 资助金额:
$ 31.75万 - 项目类别:
Characterization of NACK, an essential coactivator of Notch, in tumorigenesis
NACK(Notch 的重要共激活因子)在肿瘤发生中的表征
- 批准号:
8895283 - 财政年份:2012
- 资助金额:
$ 31.75万 - 项目类别:
PDZ-dependent jagged 1 signaling in tumorigenesis
肿瘤发生中 PDZ 依赖性锯齿状 1 信号传导
- 批准号:
8211066 - 财政年份:2008
- 资助金额:
$ 31.75万 - 项目类别:
PDZ-dependent jagged 1 signaling in tumorigenesis
肿瘤发生中 PDZ 依赖性锯齿状 1 信号传导
- 批准号:
7599162 - 财政年份:2008
- 资助金额:
$ 31.75万 - 项目类别:
PDZ-dependent jagged 1 signaling in tumorigenesis
肿瘤发生中 PDZ 依赖性锯齿状 1 信号传导
- 批准号:
8019443 - 财政年份:2008
- 资助金额:
$ 31.75万 - 项目类别:
PDZ-dependent jagged 1 signaling in tumorigenesis
肿瘤发生中 PDZ 依赖性锯齿状 1 信号传导
- 批准号:
7804572 - 财政年份:2008
- 资助金额:
$ 31.75万 - 项目类别:
PDZ-dependent jagged 1 signaling in tumorigenesis
肿瘤发生中 PDZ 依赖性锯齿状 1 信号传导
- 批准号:
7474481 - 财政年份:2008
- 资助金额:
$ 31.75万 - 项目类别:
MOLECULAR MECHANISMS OF NOTCH SIGNALING IN NEOPLASIA
肿瘤中Notch信号传导的分子机制
- 批准号:
6193488 - 财政年份:2000
- 资助金额:
$ 31.75万 - 项目类别:
Molecular Mechanisms of Notch Signaling in Neoplasia
肿瘤中Notch信号传导的分子机制
- 批准号:
8451260 - 财政年份:2000
- 资助金额:
$ 31.75万 - 项目类别:
相似国自然基金
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
- 批准号:32170319
- 批准年份:2021
- 资助金额:58.00 万元
- 项目类别:面上项目
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
- 批准号:
- 批准年份:2021
- 资助金额:58 万元
- 项目类别:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
- 批准号:31672538
- 批准年份:2016
- 资助金额:62.0 万元
- 项目类别:面上项目
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
- 批准号:31372080
- 批准年份:2013
- 资助金额:80.0 万元
- 项目类别:面上项目
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
- 批准号:81172529
- 批准年份:2011
- 资助金额:58.0 万元
- 项目类别:面上项目
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
- 批准号:81070952
- 批准年份:2010
- 资助金额:35.0 万元
- 项目类别:面上项目
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
- 批准号:30672361
- 批准年份:2006
- 资助金额:24.0 万元
- 项目类别:面上项目
相似海外基金
Role of CD44 bearing TJA-II binding glycans in therapy-resistant subset of triple negative breast cancer
携带 CD44 的 TJA-II 结合聚糖在三阴性乳腺癌耐药亚型中的作用
- 批准号:
23K06748 - 财政年份:2023
- 资助金额:
$ 31.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of methyl-CpG-binding domain protein 2 (Mbd2) in breast cancer development, progression and metastasis
甲基 CpG 结合域蛋白 2 (Mbd2) 在乳腺癌发生、进展和转移中的作用
- 批准号:
479148 - 财政年份:2023
- 资助金额:
$ 31.75万 - 项目类别:
Operating Grants
Targeting methyl-CpG-binding domain protein 2 (Mbd2) towards the development of next generation precision Epi-therapies against metastatic breast cancer
靶向甲基 CpG 结合域蛋白 2 (Mbd2),开发针对转移性乳腺癌的下一代精准外延疗法
- 批准号:
464539 - 财政年份:2022
- 资助金额:
$ 31.75万 - 项目类别:
Operating Grants
Targeting methyl-CpG-binding domain protein 2 (Mbd2) towards the development of next generation precision Epi-therapies against metastatic breast cancer
靶向甲基 CpG 结合域蛋白 2 (Mbd2),开发针对转移性乳腺癌的下一代精准外延疗法
- 批准号:
472577 - 财政年份:2022
- 资助金额:
$ 31.75万 - 项目类别:
Operating Grants
Analysis of two novel CdGAP binding partners, LIMD1 and Talin, in tension-regulated focal adhesion dynamics in breast cancer cells
乳腺癌细胞张力调节粘着斑动力学中两种新型 CdGAP 结合伴侣 LIMD1 和 Talin 的分析
- 批准号:
485998 - 财政年份:2022
- 资助金额:
$ 31.75万 - 项目类别:
Studentship Programs
ERa is a novel RNA-binding protein controlling breast cancer
ERa是一种新型RNA结合蛋白,可控制乳腺癌
- 批准号:
10580061 - 财政年份:2022
- 资助金额:
$ 31.75万 - 项目类别:
ERa is a novel RNA-binding protein controlling breast cancer
ERa是一种新型RNA结合蛋白,可控制乳腺癌
- 批准号:
10460857 - 财政年份:2022
- 资助金额:
$ 31.75万 - 项目类别:
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy
原位白蛋白结合 siRNA 用于三阴性乳腺癌肿瘤穿透和分子靶向治疗
- 批准号:
10317651 - 财政年份:2021
- 资助金额:
$ 31.75万 - 项目类别:
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy
原位白蛋白结合 siRNA 用于三阴性乳腺癌肿瘤穿透和分子靶向治疗
- 批准号:
10596246 - 财政年份:2021
- 资助金额:
$ 31.75万 - 项目类别:
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy
原位白蛋白结合 siRNA 用于三阴性乳腺癌肿瘤穿透和分子靶向治疗
- 批准号:
10737831 - 财政年份:2021
- 资助金额:
$ 31.75万 - 项目类别:














{{item.name}}会员




